MA45562B1 - Préparation pharmaceutique liquide stable - Google Patents

Préparation pharmaceutique liquide stable

Info

Publication number
MA45562B1
MA45562B1 MA45562A MA45562A MA45562B1 MA 45562 B1 MA45562 B1 MA 45562B1 MA 45562 A MA45562 A MA 45562A MA 45562 A MA45562 A MA 45562A MA 45562 B1 MA45562 B1 MA 45562B1
Authority
MA
Morocco
Prior art keywords
liquid pharmaceutical
stable liquid
pharmaceutical preparation
pharmaceutical formulation
present
Prior art date
Application number
MA45562A
Other languages
English (en)
Other versions
MA45562A (fr
Inventor
Joon Won Lee
Won Yong Han
Su Jung Kim
Jun Seok Oh
So Young Kim
Su Hyeon Hong
Yeon Kyeong Shin
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45562(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of MA45562A publication Critical patent/MA45562A/fr
Publication of MA45562B1 publication Critical patent/MA45562B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique liquide stable contenant : un anticorps ou son fragment de liaison à l'antigène ; un tensioactif ; un sucre ou son dérivé ; et un tampon. La formulation pharmaceutique liquide stable selon la présente invention a une faible viscosité tout en contenant une teneur élevée en anticorps, présente une excellente stabilité au stockage à long terme basée sur une excellente stabilité dans des conditions accélérées et des conditions sévères, et peut être administrée par voie sous-cutanée.
MA45562A 2016-06-30 2017-06-28 Préparation pharmaceutique liquide stable MA45562B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160083039 2016-06-30
PCT/KR2017/006855 WO2018004260A1 (fr) 2016-06-30 2017-06-28 Préparation pharmaceutique liquide stable

Publications (2)

Publication Number Publication Date
MA45562A MA45562A (fr) 2019-05-08
MA45562B1 true MA45562B1 (fr) 2024-05-31

Family

ID=60787364

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45562A MA45562B1 (fr) 2016-06-30 2017-06-28 Préparation pharmaceutique liquide stable

Country Status (40)

Country Link
US (3) US11951207B2 (fr)
EP (2) EP4338752A3 (fr)
JP (2) JP7082070B2 (fr)
KR (3) KR20180003452A (fr)
CN (1) CN109310628A (fr)
AU (2) AU2017287743C1 (fr)
CA (1) CA3028238C (fr)
CL (1) CL2018003662A1 (fr)
CO (1) CO2018013689A2 (fr)
CR (1) CR20180599A (fr)
CU (1) CU24561B1 (fr)
DK (1) DK3479819T5 (fr)
DO (1) DOP2018000290A (fr)
EA (1) EA201892653A1 (fr)
EC (1) ECSP18093651A (fr)
ES (1) ES2975782T3 (fr)
FI (1) FI3479819T3 (fr)
GE (1) GEP20217249B (fr)
HR (1) HRP20240426T1 (fr)
HU (1) HUE066142T2 (fr)
IL (1) IL263630B2 (fr)
JO (1) JOP20180125B1 (fr)
LT (1) LT3479819T (fr)
MA (1) MA45562B1 (fr)
MD (1) MD3479819T2 (fr)
MX (1) MX2018015960A (fr)
NI (1) NI201800139A (fr)
PE (1) PE20190448A1 (fr)
PH (1) PH12018502670B1 (fr)
PL (1) PL3479819T3 (fr)
PT (1) PT3479819T (fr)
RS (1) RS65395B1 (fr)
SG (1) SG11201811320YA (fr)
SI (1) SI3479819T1 (fr)
SM (1) SMT202400143T1 (fr)
TN (1) TN2018000443A1 (fr)
TW (1) TWI736643B (fr)
UA (1) UA122610C2 (fr)
WO (1) WO2018004260A1 (fr)
ZA (1) ZA201808476B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN120392659A (zh) 2017-01-11 2025-08-01 赛特瑞恩股份有限公司 稳定的液体调配物
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2020060183A1 (fr) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 Formation de liquide pour stabiliser un anticorps de trastuzumab
EP3865154A4 (fr) * 2018-10-10 2022-11-09 Astellas Pharma Inc. Composition pharmaceutique contenant un complexe de fragment fab d'anticorps au site anti-humain marqué
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
JP2022525556A (ja) * 2019-03-18 2022-05-17 アルヴォテック エイチエフ Ｔｎｆ－アルファ抗体の高濃度水性製剤
KR20220003562A (ko) * 2019-04-23 2022-01-10 사노피 항-cd38 항체 및 제형
CN110095615A (zh) * 2019-05-27 2019-08-06 山东艾科达生物科技有限公司 一种测定超敏c反应蛋白含量的试剂盒
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
WO2021182874A1 (fr) * 2020-03-13 2021-09-16 삼성바이오에피스 주식회사 Composition pharmaceutique liquide présentant une stabilité améliorée
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂
CN115697406A (zh) * 2020-05-29 2023-02-03 美国安进公司 抗体配制品及其用途
CN114099424B (zh) * 2020-08-25 2025-03-14 越海百奥药业(绍兴)有限公司 一种重组免疫细胞因子的制剂
KR20240073051A (ko) * 2021-09-16 2024-05-24 주식회사 에이프로젠 항-TNFα 항체를 포함하는 약제학적 조성물
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
WO2023125483A1 (fr) * 2021-12-28 2023-07-06 山东先声生物制药有限公司 Composition pharmaceutique d'anticorps anti-tnfr2
JP2025541159A (ja) * 2022-12-09 2025-12-18 ゼントリア， インコーポレイテッド サルコイドーシスをｔｎｆ－α抗体で治療する方法、並びに関連する組成物及び方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69319753T2 (de) 1992-11-19 1999-04-15 Tebro S.A., Luxembourg Automatische injektionsvorrichtung für vorgefüllte spritzen
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI2390267T1 (sl) * 2005-06-07 2013-07-31 Esbatech - A Novartis Company Llc Stabilna in topna protitelesa, ki inhibirajo TNF(alfa)
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
RU2560701C2 (ru) 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
JP2015509526A (ja) * 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
WO2013186230A1 (fr) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Formulation pharmaceutique destinée à un anticorps thérapeutique
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AU2013312300A1 (en) 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
US10066019B2 (en) * 2012-10-12 2018-09-04 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
CN106421782A (zh) * 2012-10-25 2017-02-22 米迪缪尼有限公司 稳定的低粘度抗体配制品
US20140161790A1 (en) * 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
CN105051064A (zh) 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
WO2015057910A1 (fr) 2013-10-16 2015-04-23 Oncobiologics, Inc. Formulations de tampon pour stabilité d'anticorps améliorée
CN104666242B (zh) * 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
CA2944330A1 (fr) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Composition pharmaceutique liquide d'adalimumab
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
EP3237000A1 (fr) 2014-12-23 2017-11-01 Pfizer Inc Formulation d'anticorps aqueuse stable pour des anticorps anti tnf alpha
EP3256160A1 (fr) 2015-02-13 2017-12-20 Sanofi Formulation liquide stable pour des anticorps monoclonaux
AR118191A1 (es) 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Also Published As

Publication number Publication date
EP3479819A4 (fr) 2020-02-26
AU2020201249B2 (en) 2021-07-15
HUE066142T2 (hu) 2024-07-28
HRP20240426T1 (hr) 2024-06-21
DK3479819T3 (da) 2024-04-15
SMT202400143T1 (it) 2024-05-14
CO2018013689A2 (es) 2019-01-18
EP4338752A2 (fr) 2024-03-20
AU2017287743C1 (en) 2020-10-01
CU24561B1 (es) 2022-01-13
NZ770076A (en) 2025-03-28
FI3479819T3 (fi) 2024-04-17
SI3479819T1 (sl) 2024-06-28
US20240269071A1 (en) 2024-08-15
KR20210042052A (ko) 2021-04-16
RS65395B1 (sr) 2024-04-30
CR20180599A (es) 2019-04-09
ECSP18093651A (es) 2019-01-31
LT3479819T (lt) 2024-04-25
PL3479819T3 (pl) 2024-07-01
PE20190448A1 (es) 2019-03-29
MX2018015960A (es) 2019-03-21
TW201806617A (zh) 2018-03-01
CU20180154A7 (es) 2019-08-06
AU2020201249A1 (en) 2020-03-12
KR20180097471A (ko) 2018-08-31
UA122610C2 (uk) 2020-12-10
ZA201808476B (en) 2020-08-26
BR112018076377A2 (pt) 2019-03-26
US20240269069A1 (en) 2024-08-15
PT3479819T (pt) 2024-04-15
SG11201811320YA (en) 2019-01-30
KR102397713B1 (ko) 2022-05-13
JP7082070B2 (ja) 2022-06-07
MA45562A (fr) 2019-05-08
JOP20180125B1 (ar) 2022-09-15
WO2018004260A1 (fr) 2018-01-04
NI201800139A (es) 2019-03-25
NZ748101A (en) 2020-11-27
IL263630A (en) 2019-01-31
JP2022122941A (ja) 2022-08-23
US11951207B2 (en) 2024-04-09
JP7405324B2 (ja) 2023-12-26
EA201892653A1 (ru) 2019-05-31
KR20180003452A (ko) 2018-01-09
PH12018502670A1 (en) 2019-10-07
JOP20180125A1 (ar) 2019-01-30
CA3028238A1 (fr) 2018-01-04
IL263630B2 (en) 2023-06-01
TWI736643B (zh) 2021-08-21
ES2975782T3 (es) 2024-07-15
PH12018502670B1 (en) 2023-03-24
EP3479819B1 (fr) 2024-01-24
DOP2018000290A (es) 2019-02-15
EP4338752A3 (fr) 2024-04-03
GEP20217249B (en) 2021-04-26
AU2017287743B2 (en) 2020-01-30
CL2018003662A1 (es) 2019-03-15
MD3479819T2 (ro) 2024-07-31
TN2018000443A1 (en) 2020-06-15
DK3479819T5 (da) 2024-09-09
KR102229274B1 (ko) 2021-03-18
AU2017287743A1 (en) 2018-11-22
US20210000743A1 (en) 2021-01-07
CN109310628A (zh) 2019-02-05
EP3479819A1 (fr) 2019-05-08
CA3028238C (fr) 2024-01-02
JP2019525902A (ja) 2019-09-12

Similar Documents

Publication Publication Date Title
MA45562B1 (fr) Préparation pharmaceutique liquide stable
MY193913A (en) Stable Protein Solution Formulation Containing High Concentration of an Anti-Vegf Antibody
BR112014027116A2 (pt) formulação de anticorpo
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA35136B1 (fr) Formulation pour un anticorps anti-a4b7
MA33592B1 (fr) Formulations pharmaceutiques hautement concentrées
CR20210318A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
MA37616A1 (fr) Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire.
MA40571A (fr) Composition comprenant un melange d'extraits vegetaux ou un melange de molecules contenues dans ces vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
NZ775113A (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
MA43686A (fr) Formulation liquide stable de gonadotrophines
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
BR112019025591A2 (pt) Composição farmacêutica compreendendo conjugado de fármaco-anticorpo c-met e uso do mesmo
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
FR3104905B1 (fr) Méthode de bio-contrôle pour lutter contre la propagation des champignons et oomycètes phytopathogènes
MY194758A (en) Stable liquid pharmaceutical formulation
FR2910319B1 (fr) Formulations pharmaceutiques dispersibles contenant de la fluoxetine
MA42361A1 (fr) Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one
FR3035120B1 (fr) Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition